AzTrials
AzTrials

HypoxiaNCT06596083

The Effects of Ketone Ester Supplementation During a 5 Week Live High, Train Low Altitude Training Camp

A study testing Ketone ester supplement in people with Hypoxia and Exogenous Ketosis, run by KU Leuven at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study aims to investigate the effects of post-exercise and pre-sleep exogenous ketosis via oral ketone ester supplementation during a 5 week simulated altitude training camp. Read more about this study

Who is it for?
Ages 18 to 35 yearsHealthy volunteers can take part
Conditions the study is for
Hypoxia, Exogenous Ketosis
What is being tested?
Ketone ester supplement
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
18 participants
Where
1 siteBelgium
Study dates
10 Sep 2024to 15 Oct 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Physically fit and regularly involved in physical activity (2-5h per week)
  • Good health status confirmed by a medical screening
  • Non-smoking

Who cannot join

  • Any kind of injury/pathology that is a contra-indication to perform high-intensity exercise
  • Any kind of injury/pathology that is a contra-indication for exposure to hypoxia
  • Ongoing pregnancy or breastfeeding
  • intake of any medication or nutritional supplement that is proven to affect exercise performance during the last month prior to the start of the study
  • Involvement in elite athletic training at a semi-professional or professional level
  • Exposure to altitudes higher than 1500 m during the 3 months prior to the start of the study
Show all 9Show fewer
  • Blood ferritin levels below 30 ng/mL
  • Current participation in another research trial
  • Any other argument to believe that the subject is unlikely to succesfully complete the full study protocol

Trial locations and contacts

1 site in 1 country.

Chiel Poffé contact

chiel.poffe@kuleuven.be

Belgium1 site, 1 recruiting
  • KU Leuven

    Leuven, Vlaams-Brabant, 3000

    Chiel Poffé, chiel.poffe@kuleuven.be

    Recruiting

Other trials in Belgium

About this study

This study aims to investigate the effects of post-exercise and pre-sleep exogenous ketosis via oral ketone ester supplementation during a 5 week simulated altitude training camp.

Read the detailed description

Altitude training camps, where you train at sea level but live at altitude, have become a popular way for athletes to prepare for upcoming races or events. The main aim of such training camps is to benefit from the adaptations following prolonged hypoxic exposure (increased EPO concentrations leading to an increase in oxygen carrying capacity in the blood). Recently, ketone bodies have been shown to cause similar adaptations. Therefore, this study aims to investigate whether the combination of exogenous ketosis and an altitude training camp is more beneficial compared to an altitude training camp on its own.

Participants will follow a 5 week simulated altitude training camp where they spend 75 hours per week at altitude (2000-3000 meters), while taking ketone or placebo supplements after every training sessions and before going to sleep. During these 5 weeks, they will adhere to a prescribed training plan, consisting of 5 to 7 training sessions per week. Before, after and 1 week after the training camp, their exercise performance, EPO concentrations, hemoglobin mass and VO2max will be tested.

Being tested
Placebo supplement, Ketone ester supplement
Keywords
Altitude training camp, Exercise, Live high, train low, EPO
Medical subject headings
Hypoxia, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placebo supplementDietary supplement

    oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water

  • Ketone ester supplementDietary supplement

    Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink

Study groups in NCT06596083
Study groupRoleWhat they receive
Placebo ComparatorPlacebo comparatorTraining intervention: 5 weeks of live high, train low followed by an additional 1 week of reduced training (to simulate preparation for an upcoming event or race) Dietary intervention: placebo supplement
Receives: Dietary Supplement: Placebo supplement
Experimental groupExperimentalTraining intervention: 5 weeks of live high, train low followed by an additional 1 week of reduced training (to simulate preparation for an upcoming event or race) Dietary intervention: Ketone ester supplement
Receives: Dietary Supplement: Ketone ester supplement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total hemoglobin mass

    Using the optimized CO-re-breathing method, total hemoglobin mass will be estimated

    Measured: Day 0, Day 35, Day 42

  2. Skeletal muscle capillarization

    Changes in muscle capillarization are measured using immunohistochemical anlyses

    Measured: Day 0, Day 35, Day 42

  3. Cycling exercise performance

    maximal average power output during a 30 minute time trial, cycling efficiency test and repeated sprint test

    Measured: Day 0, Day 35, Day 42

Secondary outcomes (4)
  1. Maximal oxygen uptake (VO2max)

    Using ergospirometry VO2max will be measured during a graded exercise test

    Measured: Day 0, Day 35, Day 42

  2. Change in peripheral blood flow

    Measured using duplex ultrasonography

    Measured: Day 0, Day 35, Day 42

  3. Serum EPO concentrations

    Serum EPO concentrations will be measured using a commercially available ELISA kit

    Measured: Day 0, day1, week1, week2, week3, week4, week5, day35, day42

  4. Sleep Architecture

    Polysomnography will be used to measure sleep architecture

    Measured: Day 0, day1, week 3, day35, day42

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2024
  2. Study start10 Sep 2024 (estimated)
  3. Primary completion15 Oct 2024 (estimated)
  4. Study completion15 Oct 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will go through the entire 5 week training camp and 1 week follow up while taking either ketone ester supplements (KE) or an isocaloric placebo (CON).
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
18 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06596083
Sponsor's protocol ID
S67562
Status last verified
Sep 2024
First submitted
27 Aug 2024
Last updated
19 Sep 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Ketone ester supplement in people with Hypoxia and Exogenous Ketosis, run by KU Leuven at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Wout Lauriks (+32474360778, wout.lauriks@kuleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total hemoglobin mass (time frame: Day 0, Day 35, Day 42). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in